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Abstract
Brain inflammation plays a central role in numerous brain pathologies. Microglia and astrocytes are the main effector cells
that become activated when an inflammatory process takes place within the central nervous system. a-melanocyte-
stimulating hormone (a-MSH) is a neuropeptide with proven anti-inflammatory properties. It binds with highest affinity to
the melanocortin receptor 4 (MC4R), which is present in astrocytes and upon activation triggers anti-inflammatory
pathways. The aim of this research was to identify anti-inflammatory mediators that may participate in the
immunomodulatory effects of melanocortins in glial cells. Since peroxisome proliferator-activated receptors (PPARs) have
recently been implicated in the modulation of inflammation, we investigated the effect of an a-MSH analog, [Nle4, D-Phe7]-
a-MSH (NDP-a-MSH), on PPAR-b and PPAR-c gene and protein expression in rat primary astrocytes and microglia. We
initially demonstrated that rat primary microglia express MC4R and showed that treatment with NDP-a-MSH increases
PPAR-c protein levels and strongly decreases PPAR-b levels in both astrocytes and microglia. We also showed that
extracellular signal-regulated kinase 1/2 (ERK1/2)–mediated signaling is partially involved in these effects in a cell-specific
fashion. Finally, we showed that NDP-a-MSH stimulates the release of the anti-inflammatory cytokines IL-10 and TGF-b from
microglia and astrocytes, respectively. The presented data suggest a role for IL-10 and TGF-b in the protective action of
melanocortins and a connection between MC4R pathway and that of the nuclear receptor PPAR-c. This is the first report
providing evidence that MC4R is expressed in rat primary microglia and that melanocortins modulate PPAR levels in glial
cells. Our findings provide new insights into the mechanisms underlying the activation of glial MC4R and open perspectives
for new therapeutic strategies for the treatment of inflammation-mediated brain diseases.
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Introduction
Astrocytes are the most abundant cell type in the central
nervous system (CNS). Along with microglia, the resident
macrophages of the CNS, they play a major role in the regulation
of the inflammatory responses, since they can become activated by
specific pathogenic stimuli or damage signals and modify the
expression of numerous inflammatory mediators [1].
The a-melanocyte-stimulating hormone (a-MSH) is a member
of the melanocortin family, a group of peptides derived from the
post-translational cleavage of their precursor pro-opiomelanocor-
tin (POMC), which occurs in a tissue-specific manner. a-MSH is
produced mainly in neurons of the arcuate nucleus of the
hypothalamus, in the intermediate lobe of the anterior pituitary
and in discrete groups of neurons placed between the hypothal-
amus and the medulla [2]. POMC mRNA has also been detected
in lymphocytes, monocytes, keratinocytes and melanocytes [3],
and a-MSH was shown to be released by a microglial cell line [4].
Melanocortins exert their action through the activation of five
melanocortin receptor subtypes (MC1R to MC5R), which are
coupled to G-protein and upon activation induce the increase of
cyclic AMP (cAMP) levels [5]. Several studies have also reported
the activation of the extracellular signal-regulated kinase 1/2
(ERK1/2) pathway upon MCR stimulation [6,7,8]. Particularly,
Vongs et al. have shown that the a-MSH analog [Nle4, D-Phe7]-
a-MSH (NDP-a-MSH) induces ERK-1/2 activation through
MC4R [9]. In the CNS the most widely distributed subtype of
melanocortin receptor is MC4R. We and others have demon-
strated that MC4R is the only MCR expressed in rat primary
astrocytes [10,11]. Lindberg et al. detected mRNA expression of
MC1R, MC3R, MC4R and MC5R in a human microglial cell
line [12] and, in a recent study published by Malik et al., the
authors show MC4R immunoreactivity in rat brain tissue sections
in glial cells, including microglia [13]. However, the expression
pattern of MCRs in rat primary microglia has not yet been
studied.
Protective effects of a-MSH, acting through MC4R, have been
reported in several in vivo models of ischemia and inflammation
[14], as well as in a variety of in vitro systems where it has been
shown to down-regulate the production and release of inflamma-
tory mediators [5]. Particularly, we have previously shown that a-
MSH reduces the production of nitric oxide (NO) and prosta-
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glandins (PGs) induced by lipopolysaccharide (LPS) plus interfer-
on-c (IFN-c) in astrocytes [10]. We have also shown that a-MSH,
acting via MC4R, inhibits the expression of inducible nitric oxide
synthase (iNOS) and cyclooxigenase (COX-2) in rat hypothalamus
[15]. Furthermore, we have demonstrated that a-MSH and its
synthetic analog NDP-a-MSH, through MC4R activation, induce
production of cAMP and stimulate the cAMP- protein kinase A-
cAMP responsive element binding protein (cAMP-PKA-CREB)
pathway in astrocytes [16]. NDP-a-MSH, acting through MC4R,
modulates inflammatory and apoptotic cascades in a model of
global cerebral ischemia in gerbils [17] and activation of MC4R
improves survival in a model of severe haemorrhagic shock in rats
[18]. Furthermore, NDP-a-MSH protects against traumatic brain
injury through MC4R activation [19]. These data support the
notion that protective effects of melanocortins in the CNS are
mediated mainly by MC4R activation. In a microglial cell line,
Delgado et al. showed that a-MSH inhibits TNF-a, interleukin-6
(IL-6) and NO production induced by LPS plus IFN-c, and that a-
MSH is released from microglia acting as an autocrine regulatory
factor [4]. However, the MCR subtype involved in the anti-
inflammatory action of a-MSH on microglial cells is yet to be
determined.
Peroxisome proliferator-activated receptors (PPARs) are mem-
bers of the nuclear receptor superfamily of ligand-activated
transcription factors. Upon ligand binding, these receptors form
heterodimers with retinoid X receptor and then bind specific DNA
sequences thereby modulating the expression of their target genes.
To date, three isotypes have been identified: a, b (a.k.a. d) and c,
each with a specific tissue distribution and ligand specificity, all
three found in the brain [20]. Recent studies have implicated
PPARs in the control of inflammation; their protective effects have
been described in several in vivo models of CNS disorders with an
inflammatory component [21,22,23]. In glial cells, PPARs
modulate the production of pro-inflammatory mediators such as
NO, TNF-a, IL-1b, IL-6, iNOS and COX-2 [22,24].
In this study, we sought to identify possible mechanisms
involved in the anti-inflammatory actions of melanocortins in
glial cells. We first studied the expression of the different MCRs in
rat microglial cells. We then investigated the effect of NDP-a-
MSH on PPAR-c and PPAR-b gene and protein expression and
the possible participation of the ERK-1/2 signaling pathway in
these effects. Finally, we examined the effect of NDP-a-MSH on
the release of the anti-inflammatory cytokines IL-10 and TGF-b in




Experimental procedures were approved by the Institutional
Committee for the Care and Use of Laboratory Animals
(CICUAL) of the School of Medicine, University of Buenos Aires,
Argentina (resolution nu 096/2010) and were carried out in
compliance with the guidelines of the NIH Guide for the Care and
Use of Laboratory Animals.
Reagents
NDP-a-MSH was obtained from Bachem (CA, USA). HS024
and GW9662 were purchased from Tocris Bioscience (MO, USA).
PD98059 was purchased from Merck KGaA (Darmstadt,
Germany). Fetal bovine serum (FBS) was obtained from PAA
laboratories GmBH (Pasching, Austria). DMEM/F-12, DMEM,
MEM, antibiotics and all RT-PCR reagents were purchased from
Invitrogen Life technologies (CA, USA). Biotinylated anti-rabbit
antibody was from Millipore (MA, USA). PPAR-c (H-100), PPAR-
b (H-74) and Glyceraldehyde 3- phosphate dehydrogenase
(GAPDH, FL-335) antibodies were from Santa Cruz Biotechnol-
ogies (CA, USA). MC4R antibody was purchased from Cayman
Chemical (MI, USA). MC4R primers were from Integrated DNA
Technologies, Inc. (Coralville, IA). All other media and supple-
ments were obtained from Sigma-Aldrich Corporation, unless
specified otherwise.
Primary Astrocyte and Microglial Cultures
1–2 days old Wistar rat pups were decapitated and their brains
were removed and freed from meninges. Cells were mechanically
dispersed and seeded in previously poly-L-lysine-coated culture
flasks, and maintained in DMEM/F-12 supplemented with 10%
FBS, 50 mg/ml streptomycin and 50 U penicillin, at 37uC in 5%
CO2. Medium was replaced twice a week. After 11–14 days,
microglial cells were detached from astrocytes by shaking for 1–
2 h at 110 rpm, at 33uC in a Thermo Scientific Orbital Shaker
(Thermo Fischer Scientific, Germany). Supernatants were col-
lected and centrifuged, and microglia was seeded in uncoated
plates in supplemented DMEM and left to stabilize for 24 h at
37uC in 5% CO2 before adding the drugs in fresh supplemented
DMEM containing 2% FBS and 2 mM L-glutamine. Cells were
stained with a microglial marker (anti-rat CD11b monoclonal
antibody, OX-42, Millipore) to assess their purity, which was close
to 93%.
Astroglial cultures were separated from oligodendrocytes by
shaking once every 2–3 days for 24 h at 180 rpm, at 33uC in a
Thermo Scientific Orbital Shaker (Thermo Fischer Scientific,
Germany). After 3 weeks of culture astrocytes were trypsinized,
subcultured and left to stabilize for 2–3 days at 37uC in 5% CO2.
Then they were incubated with the drugs in MEM supplemented
with 2% FBS, 6 mM L-glutamine, 50 mg/ml streptomycin and
50 U penicillin. Cultures were routinely close to 95% astrocytes, as
assessed by immunostaining with GFAP monoclonal antibody
(Millipore, MA, USA), as previously described [10].
Immunocytochemistry for MC4R
Cells were washed in phosphate buffered saline (PBS) and fixed
in PBS–formaldehyde 4% for 15 min at room temperature (RT).
Then cells were incubated in blocking solution containing 10%
donkey serum, 5% rat serum and 0.2 mL/mL avidin solution in
PBS for 1 h at RT. Subsequently, cells were incubated overnight
at 4uC with the primary antibody against MC4R (1:100) in
blocking solution containing 1% donkey serum, 0.5% rat serum
and 0.2 mL/mL biotin solution. After rinsing, slides were
incubated with a biotin-conjugated donkey anti-rabbit secondary
antibody (1:200) in blocking solution containing 1% donkey serum
for 1 h at RT. Cells were washed and incubated with FITC-
conjugated avidin (1:400 in 10 mM HEPES, pH 7.9) for 30 min
at RT, washed in PBS and mounted in mounting medium
Vectashield (Vector Laboratories). Staining was visualized in a
fluorescence microscope (Axiophot; Carl Zeiss, Jena, Germany).
Negative control slides were incubated with blocking solution
instead of primary antibody.
Reverse-transcription Polymerase Chain Reaction (RT-
PCR)
Total DNA and RNA was extracted using Trizol reagent
(Invitrogen Life technologies, CA, USA), following the manufac-
turer’s instructions. 5 mg of RNA for astrocyte samples or 3 mg of
RNA for microglial samples were treated with 1 U DNAse
(Promega Corp., Madison, WI) and reverse-transcribed as
MC4R Anti-inflammatory Actions in Glial Cells
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described before [15]. Synthetic oligonucleotides used for ampli-
fication of MCRs were: MC1R forward: 59-
TCTGCTGCCTGGCCCTGTCTGA-39, MC1R reverse: 59-
TGCTGGCACGCTCTCGTGAACA-39, MC3R forward: 59-
AGCAACCGGAGTGGCAGT-39, MC3R reverse: 59-
GGCCACGATCAAGGAGAG-39, MC4R forward: 59-
GGCTTCACATTAAGAGGATCGCT-39, MC4R reverse: 59-
TTTATGGAACTCCATAGCGCCC-39, MC5R forward: 59-
TCTTCCAGCGATGAACTCCT-39, MC5R reverse: 59-AAG-
CAAGCGCAATAGACGTT-39. PCR products were electropho-
resed in a 2% agarose gel and visualized by ethidium bromide
staining.
Real-time Quantitative PCR (qPCR)
Products of the Reverse -Transcription reaction were amplified
using specific primers and SYBR Green Master Mix (Invitrogen
Life Technologies) on a StepOneTM Real-Time PCR System
(Applied Biosystems). For astrocyte samples primers were used at a
concentration of 300 gM for PPAR-c and HPRT, and 900 gM
for PPAR-b. For microglial samples primers were used at a
concentration of 300 gM for PPAR-c and HPRT, and 450 gM
for PPAR-b. Synthetic oligonucleotides used for qPCR were:
PPAR-c forward: 59-CCCACCAACTTCGGAATCAG -39,
PPAR-c reverse: 59-GGAATGGGAGTGGTCATCCA-39,
PPAR-b forward: 59- CTCCTGCTGACTGACAGATG-39,
PPAR-b reverse: 59- TCTCCTCCTGTGGCTGTTC-39, HPRT
forward: 59-CTCATGGACTGATTATGGACAGGAC-39,
HPRT reverse: 59-CAGGTCAGCAAAGAACTTATAGCC-39.
PCR conditions were: denaturation at 95uC for 1 min, followed by
40 cycles of 95uC for 1 min and 60uC for 1 min. The PCR
product specificity was verified by a melting curve analysis. No-RT
controls were performed by omitting addition of the reverse
transcriptase enzyme, and no-template controls were performed
by addition of nuclease free water instead of cDNA. Gene
expression was normalized to the endogenous reference gene
HPRT by the relative quantitative method (DDCt) [33] using Step-
One Software (Applied Biosystems), and expressed as fold-changes
relative to the control group.
Protein Extraction and Western Blotting
Cells were scrapped in cold PBS and lysed in lysis buffer
(50 mM Tris-HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% NP-
40, 1 mM PMSF, 1 mg/mL Aprotinin, 1 mg/mL Leupeptin,
1 mg/mL Pepstatin A, 10 mM NaF, 1 mM Na3VO4). Protein
levels were quantified with Bradford’s reagent and protein samples
(30–40 mg) were subjected to electrophoretic separation on a 10%
SDS-polyacrilamide gel and then electrotransferred to a poly-
vinylidene difluoride membrane. Blots were blocked for 1.5 h at
RT in 5% non-fat dry milk-Tris-buffered saline- 0.1% Tween-20
(TBST) and incubated overnight with the appropriate primary
antibody dilution (PPAR-c 1:500, PPAR-b 1:500, GAPDH
1:10000) in 5% non-fat dry milk-TBST at 4uC. This was followed
by incubation for 1 h at RT with the respective biotinylated
secondary antibody, and 1 h incubation at RT with streptavidin-
peroxidase (Millipore, MA, USA). Immunoreactivity was detected
by chemiluminescence (Bio-Lumina, PB-L, Prod. Bio Lo´gicos,
Argentina) and semi-quantified using SCION Image software.
Data were normalized to the internal control GAPDH and
expressed as fold-changes relative to unstimulated cells.
Cytokine Assays
Cytokine release was assessed by ELISA, using commercial kits
(IL-10: BD Biosciences; TGF-b: Invitrogen). Assays were per-
formed following the manufacturer’s instructions, with the
exception of TGF-b assay buffer which was PBS with 2% heat-
inactivated FBS and 0.1% Tween-20.
Statistical Analysis
Results are expressed as mean 6 SEM of at least three
independent experiments. Data were analyzed by one sample t
test, unpaired Student’s t test or one-way analysis of variance
(ANOVA) followed by Dunnet or Bonferroni Multiple Compar-
isons Test, as required by the experimental design. GraphPad
Prism 5 Software was used (GraphPad Software, CA, USA).
Differences with a value of p,0.05 were considered statistically
significant.
Results
In the present work we focused on the study of possible
mediators of melanocortins’ anti-inflammatory actions on glial
cells. Given its greater enzymatic stability we used the synthetic
compound NDP-a-MSH [34], an analog of a-MSH that can bind
all MCRs but has greater affinity for MC4R and MC5R [35].
Melanocortin 4 Receptor Expression in Rat Microglia
Our first aim was to study MCR mRNA expression in rat
microglial cells by RT-PCR using total mRNA from untreated
primary microglial cultures. RT-PCR for MC4R yielded an
amplification product near 595 bp (as expected for MC4R) in
microglial cells. However, we did not find expression of MC1R,
MC3R or MC5R in these cells (Fig. 1.A). Protein expression was
evaluated by western blot using a specific primary antibody against
MC4R (Fig. 1.B). The blot shows the presence of a band of nearly
50 KDa in the microglial sample, as well as in astrocytes (positive
control). We also detected microglial MC4R immunoreactivity by
immunocytochemistry (Fig. 1.C). Our data confirm that rat
primary cultured microglial cells express MC4R, while mRNA
expression of the other MCR subtypes was not detected in these
cells.
NDP-a-MSH Modulates PPAR-c and PPAR-b Expression in
Microglia and Astrocytes
PPARs are known to be expressed within the brain [20]. Our
aim was to assess the expression of PPAR-c and -b in rat
astrocytes and microglia and to study their modulation by NDP-
a-MSH. We detected basal mRNA expression of PPAR-c and
PPAR-b, but we did not find a significant change in mRNA
levels after 24 h of treatment with NDP-a-MSH, both in
astrocytes (Fig. 2.A and 3.A) and in microglia (Fig. 2.C and
3.C). We then decided to investigate the effect of NDP-a-MSH
on the receptor’s protein expression, since PPARs can be
regulated at the post-transcriptional level without changes being
observed in their gene expression [36]. PPAR-c and PPAR-b
protein expression was assessed by western blot after 24 h of
treatment. NDP-a-MSH significantly induced the expression of
PPAR-c in astrocytes (Fig. 2.B) and in microglia (Fig. 2.D)
whereas it caused a remarkable decrease of PPAR-b protein
levels in both cell types (Fig. 3.B and 3.D).
ERK-1/2 Participates in the NDP-a-MSH-induced
Modulation of PPAR Protein Expression in Astrocytes and
Microglia
The finding that NDP-a-MSH modulates PPAR protein
expression led to the question of what are the mechanisms
involved in this modulation. Since stimulation of all MCRs leads
to activation of ERK-1/2 [6,7,8,9] and this kinase has been
MC4R Anti-inflammatory Actions in Glial Cells
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previously linked to the regulation of PPAR activity [37], we
evaluated whether ERK-1/2 activation is involved in NDP-a-
MSH-induced modulation of PPAR expression in our system. For
this, the effect of the MCR agonist was evaluated in the presence
of the MEK inhibitor PD98059, which inhibits the ERK-1/2
pathway [38]. The stimulatory effect of NDP-a-MSH on PPAR-c
expression was not observed in the presence of PD98059 in
astrocytes (Fig. 4.A). Similarly, the decrease in PPAR-b levels
caused by NDP-a-MSH treatment was not observed in the
presence of PD98059 in microglial cells (Fig. 4.B). The inhibitor
had no effect neither on NDP-a-MSH modulation of PPAR-c
expression in microglial cells nor on NDP-a-MSH modulation of
PPAR-b expression in astrocytes (data not shown). Our data
suggest a cell-specific role for ERK-1/2-mediated signaling, in
which this kinase would be at least partially mediating the NDP-a-
MSH-induction of PPAR-c expression in astrocytes, and the
NDP-a-MSH-induced reduction of PPAR-b levels in microglial
cells.
NDP-a-MSH Induces IL-10 Release from Microglial Cells
and TGF-b Release from Astrocytes
Our main interest was to study the modulation of anti-
inflammatory mediators by NDP-a-MSH in astrocytes and
microglial cells. To determine the effect of NDP-a-MSH on IL-
10 release culture supernatants were assayed by ELISA after
24 h of treatment. NDP-a-MSH induced IL-10 release from
microglia (Fig. 5.A). The stimulatory effect of NDP-a-MSH was
not observed in the presence of the MC4R selective antagonist
HS024 [39] (Fig. 5.B). We also found that in the presence of
the PPAR-c antagonist GW9662, NDP-a-MSH did not induce
IL-10 release from microglial cells (Fig. 5.C). However,
GW9662 decreased IL-10 release per se from these cells
(Fig. 5.D). On the other hand, IL-10 levels in the supernatant
of primary cultured astrocytes were not detectable in the
untreated group and we did not observe an effect of NDP-a-
MSH on the release of this cytokine in these cells (data not
shown). To asses the effect of the MCR agonist on TGF-b
release, culture supernatants were tested by ELISA after 6 h of
treatment. NDP-a-MSH significantly induced TGF-b release
from astrocytes (Fig. 6.A). The PPAR-c antagonist GW9662
had no effect over NDP-a-MSH-induced TGF-b release in
astrocytes (Fig. 6.B). On the other hand, TGF-b release from
microglial cells was unaffected by the treatment with NDP-a-
MSH (Fig. 6.C).
Figure 1. Melanocortin 4 receptor expression in rat microglia. (A) MCR mRNA expression was assessed by RT-PCR using total mRNA from
untreated microglial cells. Genomic DNA was used as a positive control (lane 1). A band close to 595 pb corresponding to MC4R amplification
product was detected in primary cultured microglial cells (lane 2, MC4R). We did not detect expression of the other MCR subtypes in these cells (lane
2). (B) MC4R protein expression was evaluated by western blot. Total protein sample from astrocytes was used as a positive control. Results show the
presence of a band of nearly 50 KDa in both astrocytes (lane 1) and microglia (lane 2). (C) MC4R was detected in primary microglia by
immunocytochemistry. The left panel shows MC4R immunoreactivity in microglial cells. Nuclei were stained with DAPI to identify individual cells. The
negative control is shown in the right panel.
doi:10.1371/journal.pone.0057313.g001
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Discussion
The data presented herein describe for the first time that
activation of MC4R modulates PPAR levels in rat astrocytes and
microglia. Our studies demonstrate that NDP-a-MSH treatment
increases PPAR-c levels whereas it decreases PPAR-b levels in
both cell types. Moreover, we observed that NDP-a-MSH exerts
cell-specific effects, increasing IL-10 release from microglia and
TGF-b release from astrocytes. Thus, we describe novel mecha-
nisms following MC4R activation that may be involved in the anti-
inflammatory effects of melanocortins in glial cells.Inflammation
has been implicated in the pathogenesis of several neurological
disorders such as Alzheimers disease, Parkinsons disease, Hun-
tingtons disease and Experimental Autoimmune Encephalomyeli-
tis (EAE) [40]. Melanocortin’s protective effects in models of
disease with an inflammatory component have been broadly
described, both in the periphery and in the CNS [14]. The main
candidates for mediating melanocortin’s anti-inflammatory action
in the brain are MC3 and MC4 receptors since MC3/MC4R
antagonists block the effect of a-MSH on the production of pro-
Figure 2. PPAR-c expression in rat astrocytes and microglia. (A and C) Gene expression was studied by RT-qPCR as described in Materials and
Methods. No significant change in PPAR-c mRNA levels was observed after 24 h of incubation with NDP-a-MSH in both cell types. (B and D) Protein
expression of PPAR-c was assessed by western blot after 24 h of treatment. NDP-a-MSH induced the expression of PPAR-c protein in both cell types.
Data were analyzed by one sample t Test and are expressed as mean 6 SEM. *p,0.05 vs. control group.
doi:10.1371/journal.pone.0057313.g002
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inflammatory cytokines in the CNS [10,41]. Recently, agonists of
MC4R have emerged as promising candidates for the treatment of
brain disorders [42]. NDP-a-MSH was found to exert a strong
neuroprotection, through the activation of MC4R, against damage
following cerebral ischemia and traumatic brain injury (for review
see [42]). On the other hand, a selective MC3R agonist did not
show protective effects in models of middle cerebral artery
occlusion [43] or global cerebral ischemia [17], which supports
MC4R as the main mediator of NDP-a-MSH protective effects in
the brain. In microglial cells previous studies have demonstrated
that a-MSH inhibits TNF-a, NO and IL-6 production induced by
distinct pro-inflammatory agents [4,44,45] in a concentration-
related fashion. Lindberg et al. detected mRNA expression of
MC1R, MC3R, MC4R and MC5R in a human microglial cell
line [12]. However, receptor expression often varies with cell lines
and primary cultured cells and, to our knowledge, there are no
published studies on MCR expression in primary microglial cells.
Here, we report for the first time the expression of MC4R in rat
primary microglia. These data plus the fact that this receptor is the
only MCR subtype expressed in rat primary astrocytes [10,11],
further support MC4R as a promising target for modulation of
glial activation by melanocortins.This study is also the first to
report that a MC4R agonist can induce the protein expression of
PPAR-c in glial cells. Although previous studies have shown that
activation of central MC3R and MC4R reduces PPAR-c gene
expression in hepatocytes [46] and Agouti, an endogenous MC1R
Figure 3. PPAR-b expression in rat astrocytes and microglia. (A and C) Gene expression was studied by real time quantitative RT-PCR as
described in Materials and Methods. No significant change in PPAR-b mRNA levels was detected after 24 h of incubation with NDP-a-MSH in both cell
types. (B and D) Protein expression of PPAR-b was assessed by western blot after 24 h of treatment. NDP-a-MSH markedly decreased PPAR-b protein
levels in both cell types. Data were analyzed by one sample t Test and are expressed as mean 6 SEM. ***p,0.001, **p,0.01, *p,0.05 vs. control
group.
doi:10.1371/journal.pone.0057313.g003
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antagonist, increases PPAR-c levels in adipocytes [47], a very
recent study has demonstrated that a-MSH induces both PPAR-c
upregulation and activation in B16-F10 melanoma cells [48]. In
the past few years, accumulating evidence has implicated PPARs
in the regulation of inflammatory processes in the CNS [49]. Also,
activation of PPAR-c has been found to protect cortical neurons
against NO and hydrogen peroxide-dependent toxicity [50] and
PPAR-c agonists were found to inhibit the release of pro-
inflammatory cytokines by microglial cells and astrocytes [51].
Thus, it is possible that PPAR-c could be taking part in the anti-
inflammatory effects of NDP-a-MSH in the CNS.
Our present data also indicate that NDP-a-MSH reduces
PPAR-b levels in both astrocytes and microglia. To the best of our
knowledge, there is no published data on the effect of
melanocortins on PPAR-b expression or activity. Compared to
the other isotypes much less is known about the role of PPAR-b in
the regulation of inflammatory responses. Anti-inflammatory
actions of PPAR-b agonists have been demonstrated in microglia
and astrocytes [23] and in a model of focal cerebral ischemia [52].
The fact that NDP-a-MSH treatment results in opposite effects on
PPAR-b and PPAR-c protein expression is not, however,
unexpected. This kind of inverse relationship between PPARs
has been observed previously. Jana and Pahan showed that LPS
increases PPAR-c expression whereas it decreases that of PPAR-b
in primary human astrocytes and microglia, and that treatment
with a PPAR-a agonist increases PPAR-b and decreases PPAR-c
expression in LPS-activated astrocytes and microglia [53].
Moreover, Aleshin et al. have demonstrated that both PPAR-c
and PPAR-a influence PPAR-b expression and activity in primary
astrocytes [24]. The authors point out that it is not only the
absolute levels of expression of the different PPAR isotypes but
also their ratio that will ultimately control their activity. Thus, it is
likely that a reciprocal modulation of expression between PPAR-c
and PPAR-b may be occurring in our system as well.
Unexpectedly, we found that the effect of NDP-a-MSH on
PPAR protein expression was not accompanied by a concomitant
change in PPAR’s mRNA levels. However, post-transcriptional
regulation of PPARs without observing changes in their mRNA
levels has been reported before [36,54]. Indeed, PPARs can
undergo a number of post-translational modifications such as
phosphorylation, sumoylation, ubiquitination and nitration with
cell and context-specific consequences [55]. It is plausible that the
changes observed in PPAR’s protein expression in our system
might be due to post-transcriptional mechanisms affecting
translational efficiency or protein stability and turnover. Further
study is needed to clarify this issue.
We found that ERK-1/2 signaling mediates the stimulatory
effect of NDP-a-MSH on PPAR-c levels in astrocytes but not in
microglia. MC4R stimulation triggers ERK-1/2 activation [9] and
it is known that PPARs are targets of mitogen-activated protein
kinases (MAPKs) (ERK-1/2 and p38 -MAPK) and PKA, among
other kinases, and that the consequences of phosphorylation are
varied and depend on many factors such as cellular context,
receptor isotype, the kinase involved and the affected residue [37].
Furthermore, Guntur et al. have described a mechanism by which
a kinase modulates PPAR-c expression, without altering its mRNA
levels [36]. All together, these data support the possibility that
ERK-1/2 signaling may be mediating the stimulatory effect of
NDP-a-MSH on PPAR-c protein expression in astrocytes.
In microglial cells, we found that ERK-1/2 signaling may be
involved, at least in part, in the inhibitory effect of NDP-a-MSH
on PPAR-b expression. Both cAMP and PKA activators have
been shown to increase PPAR-b activation [56] but so far there is
no evidence that ERK-1/2 signaling modulates PPAR-b activity.
There is however evidence of an inhibitory effect of PPAR-b
activation on ERK-1/2 signaling [57,58]. Further work will be
necessary to better understand the cross-talk between PPARs and
ERK-1/2 pathways in MC4R signaling in microglial cells.
As for the pathways involved in the effect of NDP-a-MSH on
PPAR-c expression in microglia and on PPAR-b expression in
astrocytes, it is important to note that ERK-1/2 is only one of the
possible downstream mediators of MC4R signaling. The activity of
AMP-activated kinase, c-jun kinase, phosphatidylinositol-3-kinase
and protein kinase C has also been shown to be modified upon
MC4R activation [59] and there is evidence that PPAR-c is a
potential target of all of these kinases [60]. Plus, MC4R activation
induces production of cAMP and stimulates the cAMP-PKA-
CREB pathway [16] and, as mentioned before, cAMP and PKA
Figure 4. ERK-1/2 partially mediates the effect of NDP-a-MSH on PPAR expression. Cells were treated for 15 min with 10mM PD98059 and
then 0.1 mM NDP-a-MSH was added to the culture medium. Cells were harvested after 24 h of incubation and PPAR protein levels were assessed by
western blot. (A) The effect of NDP-a-MSH over PPAR-c expression was not observed in the presence of PD98059 in astrocytes. (B) Similarly, the effect
of NDP-a-MSH on PPAR-b levels was not observed in the presence of PD98059 in microglial cells. Data were analyzed by one sample t Test and are
expressed as mean 6 SEM. **p,0.01 vs. control group.
doi:10.1371/journal.pone.0057313.g004
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activators have been shown to increase PPAR-b activation [56].
Thus, it is possible that one or more of these pathways may also be
involved in the modulation of PPAR expression in our model.
a-MSH has been proposed as a useful treatment for CNS
inflammatory diseases such as EAE, where it promotes the
reduction of brain infiltrates, the inhibition of pro-inflammatory
cytokines and the induction of IL-10 and TGF-b [61,62]. Our
present data indicate that NDP-a-MSH treatment increases IL-10
release from microglia, but not from astrocytes, and that this effect
is not seen in the presence of the MC4R antagonist HS024, further
supporting a role for this receptor in the observed effect of NDP-a-
MSH. IL-10 is an anti-inflammatory cytokine that is upregulated
by inflammatory stimuli in several cell types and is a key player in
the resolutory phase of the inflammatory response [63]. It has the
ability to suppress the release of NO, IL-6 and TNF-a induced by
LPS in mixed astrocyte and microglial cultures [25] and a-MSH
stimulates IL-10 release in monocytes and macrophages [26,27].
Thompson et al. demonstrated the presence of a functional PPAR
response element (PPRE) in the human IL-10 promoter region
and the upregulation of this cytokine by a PPAR-c agonist in
dendritic cells [28]. Here, we show that the stimulating effect of
NDP-a-MSH on IL-10 release in microglia is impaired in the
presence of the PPAR-c antagonist GW9662. However, we also
found that the PPAR-c antagonist reduced IL-10 release per se in
microglia. Similarly, Zapata-Gonzalez et al. found that GW9662
decreased IL-10 release per se in dendritic cells [64]. Overall, our
results indicate that PPAR-c is involved in basal IL-10 production
in microglial cells but given the inhibitory effect of the antagonist
we were unable to asses whether the stimulatory effect of NDP-a-
MSH is also exerted via PPAR-c activation. Notwithstanding, it is
possible that this receptor may be involved in NDP-a-MSH
induction of IL-10 in microglial cells.
Finally, we show that NDP-a-MSH induces TGF-b release
from astrocytes, but not from microglia. TGF-b is a cytokine that
exerts multiple functions ranging from regulation of cell prolifer-
ation, development and migration, to modulation of inflammatory
responses and CNS homeostasis [29]. This cytokine is able to
inhibit the LPS-induced expression of TNF-a in astrocytes and
microglia [30,31]. Also, in vitro studies have shown that TGF-b can
protect neurons from cell death induced by several neurotoxic
factors and that the neuroprotective effects of TGF-b are mediated
by glial cells [32]. Hence, NDP-a-MSH-induced TGF-b could be
Figure 5. IL-10 release from rat microglia. IL-10 levels in culture supernatants were quantified by ELISA after 24 h of treatment. (A) NDP-a-MSH
induced IL-10 release from microglial cells. The stimulatory effect of NDP-a-MSH is not seen in the presence of the MC4R antagonist HS024 (B) or of
the PPAR-c antagonist GW9662 (C). (D) GW9662 has an inhibitory effect per se on IL-10 release from microglia. Data were analyzed by one way
ANOVA followed by Dunnett’s or Bonferroni’s post test and are expressed as mean6 SEM. ***p,0.001, **p,0.01, *p,0.05 vs. control group, ‘p,0.05
vs. NDP-a-MSH.
doi:10.1371/journal.pone.0057313.g005
MC4R Anti-inflammatory Actions in Glial Cells
PLOS ONE | www.plosone.org 8 February 2013 | Volume 8 | Issue 2 | e57313
acting on neurons and on microglia, as it could also be acting in an
autocrine fashion on astrocytes themselves. Accumulating evi-
dence suggests that an interplay between PPAR-c and TGF-b
contributes to the regulation of cell proliferation, differentiation
and their associated cellular functions [65]. In our model, the
stimulatory effect of NDP-a-MSH on TGF-b release was not
modified by the PPAR-c antagonist GW9662, which suggests that
PPAR-c may not be involved in the effect of NDP-a-MSH on
TGF-b release. However, PPAR-c can also be activated in a
ligand-independent fashion that may not be inhibited by
GW9662, as described before [66]. Therefore, we cannot rule
out the possibility that NDP-a-MSH may be inducing TGF-b
release through PPAR-c via a ligand-independent mechanism.
The differential effects of NDP-a-MSH on IL-10 and TGF-b
release may be attributed to the cell-specific context in which
MC4R activation takes place. Many different factors intervene in
the receptor’s signaling, so that the cell-specific effects that we
observe may be understood as the result of complex interplay
between these factors. For instance, it has been suggested that
MC4R may couple to G proteins other than Gs, such as Gi/o or
Gq, thereby activating a completely different variety of signaling
pathways, and that this alternative G protein coupling may be
dependent on the ligand, the cell type involved and the level of
MC4R expression [59]. The latter two factors may be of
paramount relevance for understanding the differential responses
obtained using the same stimulus in our two primary culture
systems. We have reported that both a-MSH (the natural
endogenous hormone) and NDP-a-MSH (its synthetic analogue)
increase cAMP in a similar amount in astrocytes [16]. However, in
view of the facts discussed above, we cannot discard the possibility
that the endogenous agonist might lead to different intracellular
events than those we observed using the synthetic ligand.
In summary, we show that production of two broad spectrum
anti-inflammatory cytokines such as IL-10 and TGF-b and
modulation of PPAR expression are triggered upon glial MC4R
activation. We also propose that these mechanisms may be
involved, at least partially, in the anti-inflammatory properties of
melanocortins broadly reported in several models of neuroin-
flammation and neurodegeneration, contributing to ensure the
expression of an effective anti-inflammatory program. Collectively,
we provide new evidence supporting glial MC4R as a promising
Figure 6. TGF-b release from rat astrocytes. TGF-b levels in culture supernatants were quantified by ELISA after 6 h of treatment. (A) NDP-a-MSH
induced TGF-b release from astrocytes. (B) Treatment with 5 mM GW9662 had no effect on NDP-a-MSH-induced TGF-b release. (C) NDP-a-MSH had no
effect on TGF-b release from microglia. Data were analyzed by one way ANOVA and are expressed as mean 6 SEM. ***p,0.001, **p,0.01, *p,0.05
vs. control group.
doi:10.1371/journal.pone.0057313.g006
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target for the development of therapeutics for the treatment of
neuroinflammatory and/or neurodegenerative diseases.
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